ORLANDO, FLORIDA—Patients with low-risk prostate cancer are more likely to die with their disease than of it, according to Dr Ayal Aizer from the Brigham and Women’s Hospital, the Dana-Farber Ca
ORLANDO, FLORIDA—Patients with low-risk prostate cancer are more likely to die with their disease than of it, according to Dr Ayal Aizer from the Brigham and Women’s Hospital, the Dana-Farber Cancer Institute and Harvard University in Boston, MA — a merit-award winner at the American Society of Clinical Oncology (ASCO), American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO) 2013 Genitourinary Cancers Symposium. Treatment with surgery or radiotherapy, he explained to Peter Goodwin, adds toxicity with the potential to do harm without bringing any additional mortality benefit, for the majority of these patients.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/130310AyalAizerAJOPODCASTLoRes.mp3]
Related Episodes
Jefferson DeKloe BSc: Big US Study Confirms Benefit of HPV Vaccination for Boys as Well as Girls
The cancer prevention benefit of vaccination against the human papilloma virus cancer prevent are slowly accruing thanks to European, American and other population-based studies. I’m Peter Goodwin wi
Luis Paz-Ares MD PhD: Longer Survival Among Patients with Extensive Stage Small Cell Lung Cancer Treated with Lurbinectedin Maintenance —ASCO 2025
Luis G Paz-Ares MD PhD discdusses the addition of lurbinectedin as maintenance therapy for extensive stage small cell lung cancer (SCLC)
Frank A Sinicrope MD: Stage 3 Colon Cancer with Deficient Mismatch Repair: Big Gains from Atezolizumab Added to Standard Chemotherapy
An interview with: Frank A Sinicrope, MD, Medical Oncologist, Mayo Clinic, Rochester, Minnesota. CHICAGO —Big gains in survival have been reported among patients with stage three, node-positive colon